Page 3 - Mark Leiser News Today

A Warrensburg woman died after an SUV collided with a van in Johnson County Saturday morning.

MISSOURI STATE HIGHWAY PATROL REPORTS EIGHT FATALITIES OVER THANKSGIVING HOLIDAY

Eyal Gottlieb, PhD, has been named vice president for research at The University of Texas MD Anderson Cancer Center. Gottlieb will oversee laboratory science departments that lead discovery and translational research across multiple disciplines. He will work closely with various MD Anderson staff to implement the university’s scientific research strategy.

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.Older patients appeared to derive better OS and PFS outcomes with immunotherapy alone, findings from the exploratory pooled analysis showed.

CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.The experimental regimen conferred a 41% reduction in risk for death compared with standard chemotherapy, updated results of the randomized phase 3 ECHELON-1 trial showed.

DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.“Neoadjuvant immunotherapy is safe with the idea that definitive surgery will be performed within 4 to 8 weeks,” researcher Ramez Philips, MD, a

SALT LAKE CITY — Defibrotide benefitted adults and pediatric patients with severe or very severe veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, according to study results.The findings of the DEFIFrance study — presented at Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR — align with

A substantial portion of ductal carcinoma in situ recurrences did not appear genetically related to their primary lesions, according to study findings presented at American Association for Cancer Research Annual Meeting.De novo tumors with distinct genetic alterations accounted for nearly two in 10 recurrences, the detailed molecular analysis showed.

SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium. More than one-third of patients achieved pathologic complete response and half achieved pathologic downstaging.

Use of beta blockers did not affect outcomes among patients treated with immunotherapy for unresectable hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.Researchers reported comparable OS and overall response rates between those who used beta blockers and those who did not.